SOURCE: Equity Markets Inc

August 02, 2011 09:00 ET

Effect of Today's Deadline, Market Dynamics to Consider - Research Report on Jazz Pharmaceuticals, Inc. and Forest Laboratories, Inc.

MACAU--(Marketwire - Aug 2, 2011) - Today, announced its research report highlighting Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) and Forest Laboratories, Inc. (NYSE: FRX). Full content and research is available at

Top considerations within today's market lie with the U.S. Senate's ability to ratify a U.S. debt ceiling increase. Despite the US National Gross Domestic Product beginning to move beyond high-watermark, marking a significant shift away from recessionary pressures, continued momentum relies upon inking of the most recent tentative non-default agreement within senate before midnight tonight. The US Department of Commerce has confirmed growth within first quarter 2011, opening the strong possibility of companies within sub-sectors to experience organic revenue growth in the case of successful agreement.

No matter the outcome, opportunity is being marked for investors to take advantage of equities with high-margin and specialty products. Fundamental positives in this area are provided by limited exposure to rising commodity costs. Although raw material cost increases will continue to pressure margins, well-positioned companies can leverage organic growth and general consolidation of product lines to sustain bottom-line growth. Market-wise investors are looking to build strong cash positions to take advantage of events in the coming weeks, carefully watching for value within equities boasting established pipelines and excellent growth prospects.

Equity Markets has reviewed Jazz Pharmaceuticals, Inc. as a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. The full research report on Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ) is available here:

Equity Markets is covering Forest Laboratories, Inc. as a company that develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. The full research report on Forest Laboratories, Inc. (NYSE: FRX) is available here:

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information